Auxiliary Blood Lipid-Lowering Function Testing for Health Supplements: Standards, Methods, and Eval

Auxiliary blood lipid-lowering function testing is the scientific evaluation used to verify whether health supplements—such as fish oil, red yeast rice, plant sterol, and other nutraceutical products—genuinely deliver their claimed lipid-regulating benefits. This article presents a comprehensive technical overview of the sample types, biochemical indicators, animal models, human trial designs, analytical methods, and applicable national and international standards involved in this evaluation, supporting manufacturers pursuing product registration, claim substantiation, and quality compliance. All studies should be performed by accredited third-party laboratories operating under recognized quality management systems.

Technical Overview

Auxiliary blood lipid-lowering function testing refers to the systematic scientific assessment performed to substantiate whether a health supplement supports the regulation of serum lipid levels as claimed on the product label. Because lipid management is closely linked to cardiovascular health, regulatory authorities in major markets require robust evidence—combining quality testing, animal experiments, and human feeding trials—before a lipid-related functional claim can be authorized.

In practice, the evaluation follows a tiered structure: physicochemical and microbiological testing first confirms the identity, purity, and safety of the product; animal function experiments then establish biological plausibility using hyperlipidemic models; and finally, randomized human feeding trials demonstrate efficacy in the target population. Testing should be conducted by accredited third-party laboratories or qualified research institutions operating under ISO/IEC 17025 quality management systems, with animal and clinical studies conducted in accordance with Good Laboratory Practice principles consistent with OECD guidelines and applicable ethical requirements.

Regulatory Context and Applicable Standards

• GB 15193 series – national food safety standards for toxicological assessment procedures of food and health products
• GB 4789 series – microbiological examination methods for foods, including total plate count, coliforms, and pathogen detection
• GB 5009 series – physicochemical and contaminant analysis, including GB 5009.12 (lead), GB 5009.11 (arsenic), GB 5009.17 (mercury), GB 5009.15 (cadmium), and GB 5009.168 (fatty acid determination)
• GB/T 22251 – determination of monacolin K (lovastatin) in red-yeast-rice-based health products
• GB 5009.222 – determination of citrinin, a key contaminant controlled in fermentation-based products
• GB 14924 series and GB/T 35892 – laboratory animal nutrition and ethical review of laboratory animal welfare
• ISO/IEC 17025 – general requirements for the competence of testing and calibration laboratories
• ASTM, EN, and JIS equivalents where products are intended for international markets

Under health food regulatory frameworks such as those administered by national medical products and market regulatory authorities, the auxiliary lipid-lowering claim—increasingly phrased in some markets as "helps maintain healthy blood lipid levels"—must be substantiated through function evaluation procedures specified by the competent health authority before registration or filing approval is granted.

Testing Samples

Capsules and Softgels

Softgel capsules containing marine oils, krill oil, flaxseed oil, or blended lipid formulations are among the most common sample types. Testing focuses on omega-3 fatty acid content (EPA and DHA), oxidation status (peroxide value and acid value), and lipid function evaluation. Hard capsules typically contain powdered botanical or fermentation ingredients such as red yeast rice extract.

Tablets, Granules, and Powders

Compressed tablets, effervescent formulations, granules, and powder mixes often incorporate plant sterols or stanols, dietary fibers such as oat beta-glucan, tea polyphenols, or herbal extracts. Sample preparation requires homogenization of multiple units to ensure representative analytical portions.

Oral Liquids and Functional Beverages

Liquid preparations require verification of preservative efficacy, stability of active ingredients, and uniformity of the delivered dose. Pre-treatment steps may include extraction and concentration before instrumental or functional analysis.

Raw Materials and Functional Ingredients

Ingredient-level testing verifies identity, potency, and contaminant limits for bulk materials—fish oil concentrates, red yeast rice, phytosterol powders, algal oil, and other functional raw materials—before they are released for finished product manufacture.

Testing Items

The testing portfolio for a lipid-lowering health supplement combines functional efficacy indicators with safety and quality parameters, ensuring the product is both effective and safe for its intended consumer population.

Core Blood Lipid Biochemical Indicators

• Serum total cholesterol (TC) – primary endpoint reflecting overall cholesterol burden
• Serum triglycerides (TG) – key indicator of fat metabolism and triglyceride transport
• High-density lipoprotein cholesterol (HDL-C) – protective "good cholesterol" fraction
• Low-density lipoprotein cholesterol (LDL-C) – atherogenic "bad cholesterol" fraction
• Apolipoproteins (ApoA-I and ApoB) – supplementary markers of lipoprotein particle status
• Atherogenic indices – ratios such as LDL-C/HDL-C, TC/HDL-C, and non-HDL-C

Animal Function Evaluation Items

• Induction and validation of a diet-induced hyperlipidemia model
• Dose–response testing at low, medium, and high dose levels, typically 5, 10, and 30 times the recommended human dose
• Body weight, food intake, and organ-to-body-weight coefficient monitoring
• Optional liver lipid quantification, fecal sterol excretion, and histopathological examination

Human Feeding Trial Items

• Fasting serum lipid panel (TC, TG, HDL-C, and where applicable LDL-C) at baseline and endpoint
• Safety laboratory indicators, including hepatic and renal function, blood routine, and urinalysis
• Vital signs, physical examination, dietary records, and compliance monitoring

Safety and Quality Control Items

• Heavy metals and harmful elements: lead, arsenic, mercury, and cadmium
• Microbiological limits: total plate count, coliforms, yeasts and molds, and specified pathogens
• Functional marker compounds: EPA and DHA content, monacolin K with citrinin control for red yeast rice products, and total phytosterol content
• Stability testing, peroxide value, and acid value for oil-based products

Testing Methods

Sample Preparation and Pretreatment

Finished products are homogenized across multiple dosage units to obtain representative samples. Oils are directly prepared for derivatization or titration, while powders and tablets undergo grinding and solvent extraction. Appropriate blanks, spikes, and certified reference materials are carried through the full preparation sequence to guarantee analytical traceability.

Enzymatic Biochemical Assays

• Total cholesterol – cholesterol oxidase–peroxidase aminophenazone (CHOD-PAP) enzymatic colorimetric method
• Triglycerides – glycerol phosphate oxidase–peroxidase (GPO-PAP) enzymatic colorimetric method
• HDL-C – phosphotungstic acid–magnesium precipitation method or direct surfactant-selective enzymatic method
• LDL-C – direct enzymatic method, precipitation separation, or the Friedewald calculation when fasting triglycerides are below approximately 4.5 mmol/L
• All assays are calibrated with reference materials traceable to recognized reference measurement procedures

Animal Model Experiments

Healthy adult Sprague-Dawley or Wistar rats, or in some protocols golden hamsters whose lipoprotein metabolism more closely resembles that of humans, are fed a high-fat diet composed of basal feed supplemented with lard, egg yolk powder, cholesterol, and bile salts to induce hyperlipidemia. After model validation—serum TC or TG in the model group significantly elevated compared with the normal control—animals are randomized into model control and dose groups receiving daily gavage for approximately 30 days. Fasting blood is collected at defined time points, serum lipids are measured on an automated biochemistry analyzer, and results are evaluated statistically using analysis of variance followed by appropriate post-hoc comparisons.

Human Feeding Trials

The human trial is typically designed as a randomized, double-blind, placebo-controlled parallel study conducted in volunteers aged 18 to 65 with mild hyperlipidemia—commonly defined as fasting TC at or above 5.2 mmol/L and/or TG at or above 1.65 mmol/L—and free of lipid-lowering medication. After a dietary run-in period of about two weeks, eligible subjects are assigned to test or placebo groups with at least 30 evaluable participants per group. The intervention generally lasts 30 to 60 days, with 45 days being a commonly adopted duration. Commonly applied effectiveness criteria include a TG reduction of 15 percent or more, a TC reduction of 10 percent or more, or an HDL-C increase of 0.104 mmol/L or more in the test group compared with placebo, together with a significantly higher effective rate and no adverse safety findings. The study protocol must receive ethics committee approval, and informed consent is obtained in accordance with the Declaration of Helsinki.

Instrumental Analysis of Functional Components

Gas chromatography with flame ionization detection is used for fatty acid profiling of marine and plant oils in accordance with GB 5009.168. High-performance liquid chromatography is applied to determine monacolin K in red yeast rice products per GB/T 22251 and to quantify phytosterols and other marker compounds. Inductively coupled plasma mass spectrometry is used for elemental analysis, and liquid chromatography–tandem mass spectrometry provides confirmatory determination where required.

Result Judgment Criteria

A positive functional conclusion generally requires the following: the hyperlipidemic model is successfully established; the test groups show statistically significant reductions in TG and/or TC compared with the model control, preferably with a dose–response relationship; HDL-C is not significantly decreased; and in the human trial, improvements are significant against placebo without safety concerns. Only when efficacy and safety data are considered together can the auxiliary blood lipid-lowering function claim be regarded as scientifically substantiated.

Applications

• Health food registration and filing supporting auxiliary lipid-lowering or blood lipid health claims
• Scientific substantiation for label claims, advertising review, and marketing documentation
• Compliance support for products exported to markets with distinct claim and safety requirements
• Research and development support for formula optimization and dose determination
• Supplier qualification and incoming raw material verification
• Batch release testing, stability programs, and post-market surveillance
• Supporting data packages for academic publication and intellectual property filings

FAQ

What is the standard duration of a human feeding trial for a lipid-lowering function claim?

The intervention period typically ranges from 30 to 60 days, with 45 days being the most commonly adopted duration. This timeframe allows sufficient time for measurable changes in serum lipids while remaining practical for subject compliance. A dietary run-in period of approximately two weeks precedes the intervention to stabilize baseline lipid levels.

Which animal species are most appropriate for lipid-lowering evaluation?

Rats (Sprague-Dawley or Wistar) are the conventional choice due to well-characterized high-fat diet models and extensive historical data. Golden hamsters are increasingly used because their cholesterol and lipoprotein metabolism more closely resembles human physiology, which can improve the translational relevance of the results.

Are both animal experiments and human trials required?

For full claim substantiation in most regulatory frameworks, the function evaluation combines animal experiments demonstrating biological plausibility with human feeding trials demonstrating efficacy in the target population. The exact requirements depend on the product category and the destination market's regulatory provisions, and some filing pathways may allow simplified assessment based on recognized functional ingredients.

What defines a positive result in the evaluation?

A positive result requires statistically significant reductions in TG and/or TC relative to controls with HDL-C not adversely reduced, supported by a favorable dose–response relationship in animals and significant improvement against placebo in the human trial, all accompanied by an acceptable safety profile.

How long does the complete evaluation take?

Quality and safety testing generally requires two to four weeks, animal function experiments require approximately six to ten weeks including model induction, and human feeding trials typically require three to six months including recruitment and ethics procedures. A complete substantiation package for registration purposes commonly spans six to twelve months.